Search - tctmd.com

Displaying 521 - 540 of 702

Sort: Relevancy | Date

News Daily News

BELLO: Drug-Coated Balloons Take on De Novo Lesions vs. DES

Caitlin E. Cox

November 15, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

News Industry News

Boston Scientific Receives CE Mark Approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating

October 31, 2012

News Industry News

Tryton Presents Positive Data from More Than 900 Patients at TCT 2012 Conference in Miami

October 29, 2012

News Industry News

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

October 25, 2012

News Conference News TCT 2012

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

October 24, 2012

News Conference News TCT 2012

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

October 24, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

October 24, 2012

News Conference News TCT 2012

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

October 24, 2012

News Industry News

The Boston Scientific PROMUS Element™ Platinum Chromium Stent Demonstrates Positive Outcomes in Patients with Long Coronary Lesions

October 23, 2012

News Conference News TCT 2012

STOP-IC: Cilostazol Improves Angiographic Restenosis for Femoropopliteal Lesions After Stenting

October 23, 2012

News Industry News

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

October 23, 2012

News Conference News TCT 2012

Large Study Finds Comparable 8-Month TVF for PES, SES

October 23, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

News Conference News TCT 2012

New Results from SYNTAX, SPIRIT Trials Presented

October 22, 2012

News Conference News TCT 2012

Meta-Analyses Show Improved Outcomes with DES vs. BMS

October 22, 2012

Advertisement

BELLO: Drug-Coated Balloons Take on De Novo Lesions vs. DES

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Boston Scientific Receives CE Mark Approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating

Tryton Presents Positive Data from More Than 900 Patients at TCT 2012 Conference in Miami

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

The Boston Scientific PROMUS Element™ Platinum Chromium Stent Demonstrates Positive Outcomes in Patients with Long Coronary Lesions

STOP-IC: Cilostazol Improves Angiographic Restenosis for Femoropopliteal Lesions After Stenting

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

Large Study Finds Comparable 8-Month TVF for PES, SES

Several Trials Highlight DES Comparisons

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

New Results from SYNTAX, SPIRIT Trials Presented

Meta-Analyses Show Improved Outcomes with DES vs. BMS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content